Helix BioMedix Peptides Featured in American Academy of Dermatology Annual Meeting Research Posters Addressing Cellulite, Ros...
24 Février 2011 - 3:15PM
Business Wire
Helix BioMedix, Inc. (OTCBB:HXBM), a developer of bioactive
peptides, today announced that its peptide technologies were
featured in two posters presented at the 69th Annual Meeting of the
American Academy of Dermatology in New Orleans. The research
posters address a potential small molecule treatment program for
cellulite as well as a possible treatment for rosacea and
hyperirritable skin indications.
Entitled “Investigation into Lipolytic Compounds,” the first
poster featured results from studies of Helix’s HB2032 molecule.
HB2032 is a novel small adipocyte signaling molecule specifically
designed to address the fat deposit aspect of cellulite.
Researchers showed that HB2032 induces lipolysis, the breakdown of
stored fat, in adipocytes while also reducing the rate of
lipogenesis, or fat deposition. The molecule was designed to mimic
the body’s natural fat metabolism signaling system, which is a
critical pathway to managing cellulite.
Cellulite affects eighty to ninety percent of the adult female
population in the U.S. The condition involves the microcirculatory
system, lymphatic system, extracellular matrix and the presence of
excess subcutaneous fat that bulges into the dermis.
“The data presented at AAD and in the results of other lab
studies underscores HB2032's potential to offer a unique approach
to the topical treatment of cellulite,” said R. Stephen Beatty,
President and CEO of Helix BioMedix. “Cellulite is a challenging
and multi-faceted condition to treat. The advancement of this small
molecule option may provide deliverable bioactivity previously
unavailable in the form of a topical treatment.”
In addition, Helix BioMedix technology was also presented in a
poster by Drs. Rodan and Fields entitled “Down-regulation of
Cathelicidin Activity for Management of Rosacea-related Symptoms
and Hyperirritable Skin.” The poster discussed the use of
skin-signaling peptides and targeted protease inhibition as a means
of moderating inflammatory triggers.
The posters will be available for review at
www.helixbiomedix.com.
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company with an
extensive library of diverse bioactive peptides and patents
covering six distinct classes and hundreds of thousands of peptide
sequences. Core competencies include peptide design, synthesis and
characterization together with assay development, screening, tissue
culture and microbiology, leveraged through relationships with
contract research organizations and peptide manufacturers. The
company takes product development programs from theoretical concept
to a qualified skin care active ingredient fully validated as to
efficacy and safety. Applications for Helix BioMedix peptides
include anti-aging cosmeceutical skin care and acne treatment as
well as other topical anti-infective pharmaceuticals and wound
healing applications. Striking®, Cerakine™, and SmartPeptide™ are
trademarks of Helix BioMedix, Inc. More information about the
company and its proprietary peptides may be found on the company’s
website at www.helixbiomedix.com.
Helix Biomedix (PK) (USOTC:HXBM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Helix Biomedix (PK) (USOTC:HXBM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
